Can Wellbutrin (bupropion) be used to treat postpartum anxiety and obsessive‑compulsive disorder?

Wellbutrin is NOT recommended for postpartum anxiety or OCD

Bupropion (Wellbutrin) should not be used as a treatment for postpartum anxiety or obsessive-compulsive disorder. While it has demonstrated efficacy for postpartum depression 1, the evidence for anxiety and OCD is either absent or negative, and SSRIs remain the evidence-based first-line pharmacotherapy for these conditions in the postpartum period.

Why Bupropion Fails for Postpartum Anxiety and OCD

The OCD Evidence is Clear—and Negative

The only controlled trial of bupropion for OCD showed no efficacy 2. In this 8-week open-label study of 12 patients with OCD, bupropion 300 mg/day produced a mean YBOCS decrease of only 1.1 points—clinically meaningless. More concerning, 8 out of 12 patients (67%) experienced worsening of OCD symptoms, with a mean YBOCS increase of 21% in this subgroup 2. This bimodal response pattern suggests bupropion may actually exacerbate OCD in many patients.

SSRIs are the established first-line treatment for OCD, including postpartum OCD 3, 4, 5. Guidelines recommend 8-12 weeks of SSRI therapy, with maintenance for 12-24 months after remission 3. In postpartum OCD specifically, SSRIs (particularly fluvoxamine up to 300 mg/day) have shown 65% of patients achieving ≥30% reduction in Y-BOCS scores 5.

The Anxiety Profile is Problematic

Bupropion's stimulating properties—mediated through norepinephrine and dopamine reuptake inhibition—can provoke or worsen anxiety, particularly at higher doses 6. While some studies suggest bupropion may reduce anxiety symptoms in depressed patients with mild-to-moderate comorbid anxiety, its role remains "debated" and a "cautious approach is recommended" 6. For postpartum anxiety disorders specifically, there is no evidence base supporting bupropion use.

SSRIs and cognitive-behavioral therapy (CBT) are the evidence-based treatments for perinatal anxiety disorders 5. SSRIs led to significant improvement in both OCD and panic disorder during pregnancy and postpartum with no adverse effects on infants 5.

What About Postpartum Depression with Comorbid Anxiety/OCD?

This is where clinical judgment becomes critical:

• If the primary diagnosis is postpartum depression (with mild anxiety symptoms), bupropion has demonstrated efficacy 1. In an 8-week open-label trial, 6/8 women with postpartum depression showed ≥50% reduction in HAMD scores, with good tolerability 1.

• If OCD or significant anxiety disorder is present, SSRIs are superior because they treat both the mood and anxiety/OCD symptoms simultaneously 3, 5. The 2024 AJOG guidelines even suggest switching FROM stimulants TO bupropion for ADHD in the perinatal period when co-occurring depression exists 7—but this recommendation is based on bupropion's antidepressant properties, not anxiolytic effects.

• The systematic review on postpartum OCD pharmacotherapy found no randomized controlled trials and concluded that "studies are urgently needed" 4—but the available case reports and open-label trials all used SSRIs, not bupropion.

Safety Considerations in the Postpartum Period

The 2024 AJOG guidelines note that bupropion has "available safety data" in the perinatal period 7, with no major congenital malformations or significant adverse obstetrical outcomes, though data are limited 7. However, caution is advised during breastfeeding 7:

• Bupropion is present in human milk at very low levels
• Generally no adverse events reported
• Two case reports of seizures in breastfed infants exist 7
• Infants should be monitored for vomiting, diarrhea, jitteriness, sedation, and seizures 7

The FDA label confirms bupropion's presence in breast milk with 2% average daily infant exposure, and notes postmarketing seizure reports in breastfed infants, though causality is unclear 8.

The Correct Treatment Algorithm

For postpartum OCD:

1. First-line: SSRIs (e.g., sertraline, fluvoxamine) + CBT with exposure and response prevention 3, 4, 5
2. Adequate trial: 8-12 weeks at therapeutic doses 3
3. If partial response: Continue SSRI, augment with CBT
4. If treatment-resistant: Consider SSRI dose increase, switch to different SSRI, or augmentation strategies (antipsychotics, clomipramine, glutamatergic agents) 3

For postpartum anxiety disorders (panic, GAD, social anxiety):

1. First-line: CBT (preferred in pregnancy/breastfeeding) 5
2. If CBT insufficient or unavailable: SSRIs 5
3. Monitor infant development if breastfeeding on SSRIs

For postpartum depression alone (without significant anxiety/OCD):

1. SSRIs remain first-line
2. Bupropion is a reasonable alternative, particularly if patient has concerns about SSRI sexual side effects or weight gain 1
3. Start low (100-150 mg SR daily), titrate based on response 7

Critical Pitfalls to Avoid

1. Do not use bupropion for OCD—it may worsen symptoms in the majority of patients 2
2. Do not assume bupropion's antidepressant efficacy extends to anxiety disorders—the mechanisms are different (dopamine/norepinephrine vs. serotonin)
3. Do not overlook the seizure risk in breastfed infants—though rare, two cases have been reported 7, 8
4. Do not discontinue effective antidepressant treatment during pregnancy—women with pre-existing OCD who discontinue antidepressants have similar or worse postpartum outcomes compared to continuers 9
5. Ensure continuity of treatment—continuers with only one prescription fill during pregnancy or no fill postpartum have higher risks for postpartum psychiatric visits 9